Filter by:
  • Trial Status
  • Trial Phase
  • Age
  • Sex
  • Location

    location

    Clear All

About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

342,868 studies
in
216 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 08/05/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 08/05/2020.
Displaying: 35,566 trials in your specialties ()
View trials across your selected specialties

Study of Busulfan and FLAG Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation

  • Status
    Not yet recruiting
  • Phase
    Phase 4
  • Condition
    Leukemia
View Full Trial
INTERVENTION

Drug: Busulfan (Zhejiang Otsuka Pharmaceutical Co. Ltd), Drug: Cytarabine(Actavis Italy S.p.A), Drug: Fludarabine (Bayer), Drug: granulocyte colony-stimulating factor (KirinKunpeng), Drug: rabbit ATG(Sanofi/Genzyme)

Eligibility
  • Ages: 12 to 65 Years (Child, Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Brief Summary

The purpose of this study is to determine the safety and efficacy of Busulfan/FLAG (fludarabine, cytarabine and granulocyte colony-stimulating factor) Conditioning Regimen in Patients with Relapsed/refractory Acute Leukemia undergoing allogeneic peripheral blood stem cell transplantation.

Oral Vitamin D Treatment for the Prevention of Hepatocellular Carcinoma

  • Status
    Not yet recruiting
  • Phase
    Phase 4
  • Condition
    Hepatitis B, Carcinoma, Hepatocellular
View Full Trial
INTERVENTION

Drug: Vitamin D3

Eligibility
  • Ages: 18 to 70 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Brief Summary

The purpose of this study is to determine whether vitamin D is effective in the prevention of hepatocellular carcinoma in those patients with chronic hepatitis B.

Safety and Efficacy Study of Autologous Engineered Skin Substitute to Treat Partial- and Full-Thickness Burn Wounds

  • Status
    Not yet recruiting
  • Phase
    Phase 2
  • Condition
    Thermal Injury, Deep Partial-Thickness Burn, Full-Thickness Burn
View Full Trial
INTERVENTION

Drug: Autologous Engineered Skin Substitute, Drug: Split-Thickness Autograft (AG)

Eligibility
  • Ages: 18 to 40 Years (Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Arizona Burn Center, Pheonix, Arizona, United States

Brief Summary

The purpose of this research study is to test how well the investigational treatment, Engineered Skin Substitutes (ESS-W), works for covering and treating burn wounds. The areas of the body that are treated with ESS-W will be compared to similar areas treated with the patient's own skin (split-thickness skin autograft (AG)). A skin autograft (AG) will be performed by taking healthy skin from one area of the body and placing it on the burned area.

Erythropoietin in Management of Neonatal Hypoxic Ischemic Encephalopathy

  • Status
    Not yet recruiting
  • Phase
    Phase 3
  • Condition
    Hypoxic-Ischemic Encephalopathy
View Full Trial
INTERVENTION

Drug: normal saline, Drug: Erythropoietin

Eligibility
  • Ages: up to 24 / (18 to 64 years)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Brief Summary

Perinatal hypoxic-ischaemic encephalopathy occurs in one to three infants per 1000 term births, and up to 12 000 infants are affected each year in the united state of America. Hypoxic ischemic encephalopathy is not preventable in most cases, and therapies are limited. Hypothermia improves outcomes and is the current standard of care. Yet clinical trials suggest that 44% to 53% of infants who receive hypothermia will die or suffer moderate to severe neurological disability. Therefore, novel neuroprotective therapies are urgently needed to further reduce the rate and severity of neurodevelopmental disabilities resulting from hypoxic ischemic encephalopathy. Erythropoietin is a novel neuroprotective agent, with remarkable neuroprotective and neuroregenerative effects in animals. Rodent and primate models of neonatal brain injury support the safety and efficacy of multiple erythropoietin doses for improving histological and functional outcomes after hypoxia-ischaemia.

Inflammatory Response In Schizophrenia

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Schizophrenia
View Full Trial
INTERVENTION

Drug: Natalizumab, Other: Placebo: normal saline

Eligibility
  • Ages: 18 to 50 Years (Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
Locations

Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom

Brief Summary

Schizophrenia affects a significant proportion of the population and current levels of understanding of the illness is inadequate to treat it effectively. Converging lines of evidence suggest that neuroinflammation occurs in schizophrenia, and specifically over-activity of brain-resident immune cells called microglia. It is however unclear whether activated microglia play a primary role in schizophrenia, or whether this is a secondary phenomenon of no pathophysiological significance. The investigators therefore plan to test the effect of a monoclonal antibody (natalizumab) on psychotic symptoms in a cohort of first episode psychosis patients.

Clinic Study of 18F-Al-NOTA-MATBBN in Cancer Diagnostics

  • Status
    Not yet recruiting
  • Phase
    Early Phase 1
  • Condition
    Breast Neoplasms, Prostatic Neoplasms
View Full Trial
INTERVENTION

Drug: 18F-Al-NOTA-MATBBN PET/CT, Device: PET/CT

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
Locations

Brief Summary

The purpose of this study is to determine whether 18F-Al-NOTA-MATBBN is safety and effective for cancer diagnosis.

OCT Based Edge and In-stent Vascular Response After Cordimax Stent in patIents With NSTE-ACS

  • Status
    Not yet recruiting
  • Phase
    Phase 4
  • Condition
    Angina, Unstable, Non-ST-Segment Elevation Myocardial Infarction
View Full Trial
INTERVENTION

Device: OCT, Device: eLuting stent

Eligibility
  • Ages: 18 to 75 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Brief Summary

This study evaluates the completeness of strut coverage and vessel wall response, at different time points (3-6-12 Months), following CordimaxTM stent implantation in patients with non-ST elevation acute coronary syndrome

The Effect of Intra-Articular Injection of RegenoGel-OSP™ (Self-Plasma) and RegenoGel™ on Knee Pain in People Suffering From Osteoarthritis

  • Status
    Active, not recruiting
  • Phase
    Phase 4
  • Condition
    Osteoarthritis, Knee
View Full Trial
INTERVENTION

Device: RegenoGel-OSP, RegenoGel

Eligibility
  • Ages: 55 to 80 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Hadassah Medical Center, Jerusalem, Israel

Brief Summary

This study evaluates the efficacy of intra-articular administration of RegenoGel-OSP™ and RegenoGel™ to treat knee pain and effect on subject's activity and quality of life. During the study the subjects will receive two treatments at a 3-month interval. The study is double-blinded. The subjects will be randomized and sequentially assigned to RegenoGel-OSP™, RegenoGel or placebo treatment in the first treatment. In the second treatment after interval of three months all the subjects will necessarily receive one of the two active products. The follow-up period will continue for one year after first treatment.

Study of BTK Inhibitor BGB-3111 in Subjects With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Diffuse Large B Cell Lymphoma
View Full Trial
INTERVENTION

Drug: BGB-3111

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Peking University Cancer Hospital, Beijing, Beijing, China

Brief Summary

Screening (up to 28 days); daily treatment until disease progression, unacceptable toxicity or death, withdrawal of consent, lost to follow-up, or study termination from sponsor; treatment (up to 2 years), safety follow-up (30 days); survival follow-up until data cutoff for final analysis.

A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Osteosarcoma
View Full Trial
INTERVENTION

Drug: Avelumab, Other: Questionnaires

Eligibility
  • Ages: 12 to 49 Years (Child, Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Children's Hospital Los Angeles, Los Angeles, California, United States

Brief Summary

This clinical trial seeks to determine if avelumab will be effective in facilitating removal of all gross tumor in the event of a relapse of osteosarcoma in pediatric patients. Avelumab will be evaluated using dosing that has previously been determined in adult studies. Primary Objectives: - To estimate the response rate to 4 cycles of avelumab in patients with recurrent or progressive osteosarcoma. - To estimate the 16-week progression free survival of patients with recurrent or progressive osteosarcoma after treatment with avelumab. Secondary Objective: - To describe the toxicities associated with the administration of avelumab in patients with recurrent or progressive osteosarcoma. - To assess the quality of life of patients with recurrent or progressive osteosarcoma undergoing treatment with avelumab, and to explore relationships between clinical factors and patient-reported health-related quality of life (HRQOL) outcomes. Exploratory Objectives: - To explore factors associated with response in patients treated with avelumab after recurrent or progressive osteosarcoma (e.g. tumor PD-L1 expression). - To measure parameters of immune activation including subsets of peripheral blood mononuclear cells (PBMCs) and serum markers of immune activation. - To evaluate the role of T-cells in immune checkpoint blockade via measures of cell proliferation, co-inhibitory receptor expression on CD8 T cells, T cell repertoire, and epigenetic programming.